LENZ Therapeutics, Inc.
Public company- Headquarters
- SOLANA BEACH, California
- Industry
- Biotechnology
- Ticker
- LENZ
- CIK
- 0001815776
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| CEOEvert Schimmelpennink | Oct 28, 2026 | Departed |
| CEODaniel Chevallard | Oct 28, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- Vir Biotechnology, Inc.
Class III director appointed: Suzanne Topalian, M.D.
- AMGEN INC
director appointed: David W. Gibbs
- Cardiff Oncology, Inc.
CMO appointed: Leila Alland
- Vaxart, Inc.
member of the Board appointed: Raquel C. Bono, M.D., M.B.A., FACS
- Executive departure
CEO departs: Evert Schimmelpennink
Evert Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics, Inc., resigns the role, effective December 1, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 28, 2026Role: President and Chief Executive Officer
- Executive appointment
CEO appointed: Daniel Chevallard
Daniel Chevallard was named Interim President and CEO of LENZ Therapeutics, Inc., effective December 1, 2026. Daniel Chevallard succeeds Evert Schimmelpennink. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 28, 2026Role: Interim President and CEO
- Executive appointment
CEO appointed: Daniel Chevallard
Daniel Chevallard was named Interim President and CEO of LENZ Therapeutics, Inc., effective December 1, 2026. Daniel Chevallard succeeds Evert Schimmelpennink. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 28, 2026Role: Interim President and CEO
Last verified Nov 8, 2026